Congratulations to our long-time collaboration partners Chia Tai Tianqing Pharmaceutical Group (CTTQ) and Janssen Pharmaceuticals Inc. for reaching an exclusive license agreement. Under the agreement, CTTQ grants Janssen rights to develop and commercialize an undisclosed immuno-modulating agent to treat chronic hepatitis B virus (HBV) infection globally outside China. CTTQ is a well-established Chinese pharmaceutical company that WuXi has been working with since 2013 to discover anti-HBV small-molecule drugs. We provided end-to-end integrated research services on the compound that is the subject of this license agreement.
Hepatitis B is a serious and potentially fatal infectious disease afflicting more than 350 million patients worldwide. China has the world’s largest hepatitis B patient population and currently there is no cure for the disease. We are proud to have played a part in this collaboration to bring an innovative drug candidate closer to hepatitis B patients in China and around the world.